Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning

Sharron Schneider, Weina Chen, Janet Hou, Charles Jr Steenbergen, Elizabeth Murphy

Research output: Contribution to journalArticle

Abstract

We examined the effect of inhibition of p38 mitogen-activated protein kinase (MAPK) α/β during ischemia and preconditioning by using the inhibitor SB-202190. Isolated rat hearts were perfused with Krebs-Henseleit buffer, while left ventricular developed pressure (LVDP) and 31P nuclear magnetic resonance spectra were acquired continuously. After 20 min of ischemia and 25 min of reperfusion, recovery of LVDP in untreated hearts was 32 ± 4%, whereas hearts treated with SB-202190 5 min before ischemia recovered 59 ± 7% of their pretreatment LVDP. Preconditioning improved functional recovery to 65 ± 5%, which was unaffected by SB-202190 treatment, added either throughout the preconditioning protocol (56 ± 5% recovery) or during the final reperfusion period of preconditioning (71 ± 11% recovery). Necrosis was assessed after 40 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride (TTC) staining and creatine kinase release. The untreated group had 54 ± 8% necrotic myocardium, whereas the SB-202190-treated group had 32 ± 7% and the preconditioned group had 21 ± 4% necrotic tissue by TTC staining.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume280
Issue number2 49-2
StatePublished - Feb 2001
Externally publishedYes

Fingerprint

p38 Mitogen-Activated Protein Kinases
Ventricular Pressure
Ischemia
Reperfusion
Wounds and Injuries
Staining and Labeling
Creatine Kinase
Myocardium
Necrosis
Magnetic Resonance Spectroscopy
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole
triphenyltetrazolium

Keywords

  • P nuclear magnetic resonance
  • Intracellular pH
  • Left ventricular developed pressure
  • Necrosis
  • SB-202190

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. / Schneider, Sharron; Chen, Weina; Hou, Janet; Steenbergen, Charles Jr; Murphy, Elizabeth.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 280, No. 2 49-2, 02.2001.

Research output: Contribution to journalArticle

@article{39f88964a418491bbd73d0f4d633136c,
title = "Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning",
abstract = "We examined the effect of inhibition of p38 mitogen-activated protein kinase (MAPK) α/β during ischemia and preconditioning by using the inhibitor SB-202190. Isolated rat hearts were perfused with Krebs-Henseleit buffer, while left ventricular developed pressure (LVDP) and 31P nuclear magnetic resonance spectra were acquired continuously. After 20 min of ischemia and 25 min of reperfusion, recovery of LVDP in untreated hearts was 32 ± 4{\%}, whereas hearts treated with SB-202190 5 min before ischemia recovered 59 ± 7{\%} of their pretreatment LVDP. Preconditioning improved functional recovery to 65 ± 5{\%}, which was unaffected by SB-202190 treatment, added either throughout the preconditioning protocol (56 ± 5{\%} recovery) or during the final reperfusion period of preconditioning (71 ± 11{\%} recovery). Necrosis was assessed after 40 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride (TTC) staining and creatine kinase release. The untreated group had 54 ± 8{\%} necrotic myocardium, whereas the SB-202190-treated group had 32 ± 7{\%} and the preconditioned group had 21 ± 4{\%} necrotic tissue by TTC staining.",
keywords = "P nuclear magnetic resonance, Intracellular pH, Left ventricular developed pressure, Necrosis, SB-202190",
author = "Sharron Schneider and Weina Chen and Janet Hou and Steenbergen, {Charles Jr} and Elizabeth Murphy",
year = "2001",
month = "2",
language = "English (US)",
volume = "280",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2 49-2",

}

TY - JOUR

T1 - Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning

AU - Schneider, Sharron

AU - Chen, Weina

AU - Hou, Janet

AU - Steenbergen, Charles Jr

AU - Murphy, Elizabeth

PY - 2001/2

Y1 - 2001/2

N2 - We examined the effect of inhibition of p38 mitogen-activated protein kinase (MAPK) α/β during ischemia and preconditioning by using the inhibitor SB-202190. Isolated rat hearts were perfused with Krebs-Henseleit buffer, while left ventricular developed pressure (LVDP) and 31P nuclear magnetic resonance spectra were acquired continuously. After 20 min of ischemia and 25 min of reperfusion, recovery of LVDP in untreated hearts was 32 ± 4%, whereas hearts treated with SB-202190 5 min before ischemia recovered 59 ± 7% of their pretreatment LVDP. Preconditioning improved functional recovery to 65 ± 5%, which was unaffected by SB-202190 treatment, added either throughout the preconditioning protocol (56 ± 5% recovery) or during the final reperfusion period of preconditioning (71 ± 11% recovery). Necrosis was assessed after 40 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride (TTC) staining and creatine kinase release. The untreated group had 54 ± 8% necrotic myocardium, whereas the SB-202190-treated group had 32 ± 7% and the preconditioned group had 21 ± 4% necrotic tissue by TTC staining.

AB - We examined the effect of inhibition of p38 mitogen-activated protein kinase (MAPK) α/β during ischemia and preconditioning by using the inhibitor SB-202190. Isolated rat hearts were perfused with Krebs-Henseleit buffer, while left ventricular developed pressure (LVDP) and 31P nuclear magnetic resonance spectra were acquired continuously. After 20 min of ischemia and 25 min of reperfusion, recovery of LVDP in untreated hearts was 32 ± 4%, whereas hearts treated with SB-202190 5 min before ischemia recovered 59 ± 7% of their pretreatment LVDP. Preconditioning improved functional recovery to 65 ± 5%, which was unaffected by SB-202190 treatment, added either throughout the preconditioning protocol (56 ± 5% recovery) or during the final reperfusion period of preconditioning (71 ± 11% recovery). Necrosis was assessed after 40 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride (TTC) staining and creatine kinase release. The untreated group had 54 ± 8% necrotic myocardium, whereas the SB-202190-treated group had 32 ± 7% and the preconditioned group had 21 ± 4% necrotic tissue by TTC staining.

KW - P nuclear magnetic resonance

KW - Intracellular pH

KW - Left ventricular developed pressure

KW - Necrosis

KW - SB-202190

UR - http://www.scopus.com/inward/record.url?scp=0035008371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035008371&partnerID=8YFLogxK

M3 - Article

C2 - 11158945

AN - SCOPUS:0035008371

VL - 280

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 2 49-2

ER -